

**MULTISCREEN™ STABLE CELL LINE  
RAT RECOMBINANT GLP-2 RECEPTOR**

**Data sheet**

**PRODUCT INFORMATION**

**Catalog Number:** Cr1268

**Lot Number:** Cr1268-102615

**Quantity:** 1 vial ( $2 \times 10^6$ ) frozen cells

**Freeze Medium:** Sigma Freezing Medium (C-6164)

**Host cell:** HEK293T

**Transfection:** Expression vector containing full-length rat GLP-2 cDNA (GenBank Accession Number NM\_021848.1) with FLAG tag sequence at N-terminus

**Recommended Storage:** Liquid nitrogen upon receiving


**Propagation Medium:** DMEM, 10% FBS, 1  $\mu$ g/mL puromycin

**Stability:** In progress

**Background:** Glucagon-like peptide 2 receptor belongs to the glucagon-secretin receptor superfamily of GPCRs. The human GLP-2 receptor gene is localized on chromosome 17p13.3. The GLP-2 receptor exhibits ~50% amino acid identity with GLP-1 receptor. GLP-2 receptor binds to Glucagon-like peptide-2 (GLP-2) is a nutrient-responsive hormone and activates adenylate cyclase pathway and to a lesser extent activates MAP kinases. GLP-2 receptors are found in the central nervous system and gastrointestinal tract, with the highest expression levels in jejunum. The principal role of GLP-2 receptors appears to be the maintenance of the growth, nutrient absorption, cell proliferation, apoptosis, mucosal blood flow and suppressing gastric motility and secretion. The regenerative and cytoprotective properties of GLP-2 contribute to its therapeutic potential for the treatment of patients with intestinal disease. Recent studies have suggested that GLP-2 not only modulates intestinal stem cell behavior but may also promote carcinogenesis in models of sporadic colon cancer. Further consideration of the molecular cross-talk and downstream signaling pathways mediating the intestinotropic effects of GLP-2 is important. A detailed delineation of the signaling pathways activated by gut peptide GPCRs, as exemplified by GLP-1 and GLP-2, may provide new therapeutic targets for the treatment of human disorders such as diabetes and intestinal disease, respectively

**Application:** Functional assays

**Figure 1**



**Figure 1.** Dose-dependent stimulation of intracellular cAMP level upon treatment with ligand, measured with Multiscreen™ TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01). **Figure 2.** Receptor expression on cell surface measured by flow cytometry (FACS) using an anti-FLAG antibody. Thin line: parental cells; thick line: receptor-expressing cells.

**References:**

Jennifer L. Estall and Daniel J. Drucker (2003) Dual Regulation of Cell Proliferation and Survival via Activation of Glucagon-Like Peptide-2 Receptor Signaling J. Nutr. 133: 3708–3711.

Rocha *et al* (2004) Glucagon-like peptide-2: divergent signalling pathways. J.Surg.Res. 121: 5-9.

Brubaker and Drucker (2004) Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinol. 145: 2653-2659.

**FOR RESEARCH USE ONLY.**

Multispan Inc. All rights reserved. No part of this document may be reproduced in any form without prior permission in writing.

**Figure 2**

